REG - AstraZeneca PLC - Director Declaration

AstraZenecaAnnouncement

08/06/2018 07:05

RNS Number : 7080Q
AstraZeneca PLC
08 June 2018
 


8 June 2018 07:00 BST
 
Director Declaration
 
AstraZeneca PLC (the Company) today announced that Philip Broadley, a Non-Executive Director of the Company, was appointed as a director of Stallergenes Greer plc following the conclusion of its Annual General Meeting of Shareholders with effect from 7 June 2018.
 
This announcement is made pursuant to Listing Rule 9.6.14 R (2).
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen


 
 


+44 203 749 5712




Josie Afolabi






+44 203 749 5631




Craig Marks


Finance; Fixed Income; M&A


+44 7881 615 764




Henry Wheeler


Oncology


+44 203 749 5797




Mitchell Chan


Oncology; Other


+1 240 477 3771




Christer Gruvris


Brilinta; Diabetes


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277































Adrian Kemp

Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNQDLFBVQFFBBQ